Success Metrics

Clinical Success Rate
33.3%

Based on 1 completed trials

Completion Rate
33%(1/3)
Active Trials
1(25%)
Results Posted
200%(2 trials)
Terminated
2(50%)

Phase Distribution

Ph phase_3
1
25%
Ph phase_1
2
50%
Ph phase_2
1
25%

Phase Distribution

2

Early Stage

1

Mid Stage

1

Late Stage

Phase Distribution4 total trials
Phase 1Safety & dosage
2(50.0%)
Phase 2Efficacy & side effects
1(25.0%)
Phase 3Large-scale testing
1(25.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

33.3%

1 of 3 finished

Non-Completion Rate

66.7%

2 ended early

Currently Active

1

trials recruiting

Total Trials

4

all time

Status Distribution
Active(1)
Completed(1)
Terminated(2)

Detailed Status

Terminated2
Completed1
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
1
Success Rate
33.3%
Most Advanced
Phase 3

Trials by Phase

Phase 12 (50.0%)
Phase 21 (25.0%)
Phase 31 (25.0%)

Trials by Status

completed125%
terminated250%
active_not_recruiting125%

Recent Activity

1 active trials
Showing 4 of 4
completedphase_1

Evaluation of SAR408701 in Japanese Patients With Advanced Malignant Solid Tumors

NCT03324113
active_not_recruitingphase_3

SAR408701 Versus Docetaxel in Previously Treated, Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Positive Metastatic Non-squamous Non-small-cell Lung Cancer Patients

NCT04154956
terminatedphase_2

Tusamitamab Ravtansine (SAR408701) in Combination With Ramucirumab or Ramucirumab and Pembrolizumab in Pretreated Patients With NSQ NSCLC (CARMEN-LC04)

NCT04394624
terminatedphase_1

Evaluation of SAR408701 in Patients With Advanced Solid Tumors

NCT02187848

Clinical Trials (4)

Showing 4 of 4 trials
NCT03324113Phase 1

Evaluation of SAR408701 in Japanese Patients With Advanced Malignant Solid Tumors

Completed
NCT04154956Phase 3

SAR408701 Versus Docetaxel in Previously Treated, Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Positive Metastatic Non-squamous Non-small-cell Lung Cancer Patients

Active Not Recruiting
NCT04394624Phase 2

Tusamitamab Ravtansine (SAR408701) in Combination With Ramucirumab or Ramucirumab and Pembrolizumab in Pretreated Patients With NSQ NSCLC (CARMEN-LC04)

Terminated
NCT02187848Phase 1

Evaluation of SAR408701 in Patients With Advanced Solid Tumors

Terminated

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4